Columbus Circle Investors Cut By $11.11 Million Its Cognex (CGNX) Stake; Mobileye NV (MBLY) SI Decreased By 30.54%

October 12, 2017 - By Adrian Mccoy

Columbus Circle Investors decreased Cognex Corp (CGNX) stake by 38.41% reported in 2017Q2 SEC filing. Columbus Circle Investors sold 132,209 shares as Cognex Corp (CGNX)’s stock rose 18.92%. The Columbus Circle Investors holds 211,960 shares with $18.00 million value, down from 344,169 last quarter. Cognex Corp now has $10.22 billion valuation. The stock rose 0.45% or $0.53 reaching $118.01. About 81,337 shares traded. Cognex Corporation (NASDAQ:CGNX) has risen 131.00% since October 12, 2016 and is uptrending. It has outperformed by 114.30% the S&P500.

Mobileye NV (OTCMKTS:MBLY) had a decrease of 30.54% in short interest. MBLY’s SI was 486,900 shares in October as released by FINRA. Its down 30.54% from 701,000 shares previously. With 560,200 avg volume, 1 days are for Mobileye NV (OTCMKTS:MBLY)’s short sellers to cover MBLY’s short positions. About 32,366 shares traded. Mobileye NV (OTCMKTS:MBBYF) has 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Mobileye N.V. is engaged in the development of computer vision and machine learning sensing, mapping and driving policy technology for advanced driver assistance systems and autonomous driving technologies. The company has market cap of $13.83 billion. The Firm operates through two divisions: Original Equipment Manufacturing, which supplies the software algorithms and EyeQ chip, and After Market, which sells a complete system, which includes its software algorithms and EyeQ chip, as well as the camera and other necessary components. It has a 123.99 P/E ratio. The Company’s software algorithms and EyeQ chips perform detailed interpretations of the visual field in order to anticipate possible collisions with other vehicles, pedestrians, cyclists, animals, debris and other obstacles.

Columbus Circle Investors increased Sarepta Therapeutics Inc (NASDAQ:SRPT) stake by 14,336 shares to 48,363 valued at $1.63M in 2017Q2. It also upped Novartis A G (NYSE:NVS) stake by 4,966 shares and now owns 34,876 shares. Humana Inc (NYSE:HUM) was raised too.

Analysts await Cognex Corporation (NASDAQ:CGNX) to report earnings on October, 30. They expect $1.05 EPS, up 114.29% or $0.56 from last year’s $0.49 per share. CGNX’s profit will be $90.93 million for 28.10 P/E if the $1.05 EPS becomes a reality. After $0.63 actual EPS reported by Cognex Corporation for the previous quarter, Wall Street now forecasts 66.67% EPS growth.

Among 16 analysts covering Cognex Corporation (NASDAQ:CGNX), 7 have Buy rating, 1 Sell and 8 Hold. Therefore 44% are positive. Cognex Corporation had 31 analyst reports since August 4, 2015 according to SRatingsIntel. CLSA maintained the stock with “Underperform” rating in Tuesday, August 2 report. CLSA downgraded the stock to “Outperform” rating in Tuesday, November 3 report. The stock has “Buy” rating by Deutsche Bank on Thursday, December 8. FBR Capital initiated the stock with “Mkt Perform” rating in Wednesday, November 11 report. The stock has “Outperform” rating by Raymond James on Friday, January 22. Credit Agricole downgraded the shares of CGNX in report on Tuesday, November 3 to “Outperform” rating. Cowen & Co maintained the stock with “Buy” rating in Friday, September 8 report. Canaccord Genuity downgraded the stock to “Hold” rating in Tuesday, August 4 report. The stock of Cognex Corporation (NASDAQ:CGNX) earned “Buy” rating by Canaccord Genuity on Wednesday, November 18. The rating was maintained by Needham on Tuesday, November 1 with “Buy”.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.